Hormone Replacement Therapy

A few weeks ago, I wrote about being a little behind with planting my seedlings. I’m pleased to report they’re doing well! A few are also, apparently, “leggy.” A term I’ve only just learned, which sounds far more charming than it is. In practice, it means they’ve stretched a bit too eagerly toward the light and, in doing so, sacrificed some structural integrity.

There are topics in medicine where the data evolve slowly and cautiously. And then there are topics where the data have been sitting, quite patiently, waiting for us to catch up. Hormone replacement therapy (HRT) after risk-reducing oophorectomy in BRCA mutation carriers falls squarely into the latter category. The evidence is not new. It is not particularly controversial. And yet, the clinical hesitation persists, and patients are being negatively impacted.